Calendrier des promotions PharmaCyte Biotech, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.Paramètres de base
IPO date
2010-09-17
ISIN
US71715X2036
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
Nom | Signification | Grade |
P/S | 0 | 0 |
P/BV | 0.514 | 10 |
P/E | 60.86 | 1 |
Efficacité
Nom | Signification | Grade |
ROA | 0.5012 | 1 |
ROE | 0.5949 | 1 |
ROIC | 0 | 0 |
Dividendes
Nom | Signification | Grade |
Rendement en dividendes | 0 | 0 |
DSI | 0 | 0 |
Croissance moyenne du dividende | 0 | 0 |
Devoir
Nom | Signification | Grade |
Debt/EBITDA | 0 | 10 |
Debt/Ratio | 0 | 10 |
Debt/Equity | 0.516 | 9 |
Impulsion de croissance
Nom | Signification | Grade |
Rentabilité Revenue, % | -98.14 | 0 |
Rentabilité Ebitda, % | -108.78 | 0 |
Rentabilité EPS, % | -1344.13 | 0 |
paper.price.prices
Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
common.calendar.number_days.1 | 1.01 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
common.calendar.number_days.7d | 1.08 $ | 0 $ | 0 $ | -6.48 % | 0 % | 0 % |
common.calendar.number_days.30d | 1.05 $ | 1.01 $ | 1.08 $ | -3.81 % | 0 % | 0 % |
common.calendar.number_days.90d | 1.23 $ | 1.01 $ | 1.27 $ | -17.89 % | 0 % | 0 % |
common.calendar.number_days.180d | 1.49 $ | 1.01 $ | 1.81 $ | -32.21 % | 0 % | 0 % |
common.calendar.number_days.1y | 1.53 $ | 1.01 $ | 2.18 $ | -33.99 % | 0 % | 0 % |
common.calendar.number_days.3y | 2.6 $ | 1.01 $ | 3.18 $ | -61.15 % | 0 % | 0 % |
common.calendar.number_days.5y | 0.0161 $ | 0.0042 $ | 16.9 $ | 6173.29 % | 0 % | 0 % |
common.calendar.number_days.10y | 0.0042 $ | 0.0042 $ | 16.9 $ | 24047.62 % | 0 % | 0 % |
common.calendar.number_days.ytd | 1.58 $ | 1.01 $ | 1.81 $ | -36.08 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
Superviseur | Titre d'emploi | Paiement | Année de naissance |
Mr. Joshua N. Silverman | Interim CEO, Interim President & Interim Chairman | 197.92k | 1970 (55 années) |
Mr. Carlos A. Trujillo CPA, CPA | Chief Financial Officer | 380k | 1958 (67 années) |
Dr. Jose L. Iglesias M.D. | Consulting Chief Medical Officer | N/A | 1957 (68 années) |
Dr. Hans-Peter Hammes | Member of Medical & Scientific Advisory Board and Consultant | N/A |
Informations sur l'entreprise
Adresse: United States, Las Vegas. NV, 3960 Howard Hughes Parkway - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://pharmacyte.com
Site web: https://pharmacyte.com